George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745–59.

Article  CAS  PubMed  Google Scholar 

Romankiewicz JA, Brogden RN, Heel RC, Speight TM, Avery GS. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983;25:6–40.

Article  CAS  PubMed  Google Scholar 

Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019. Mayo Clin Proc. 2020;95:1222–30.

Article  CAS  PubMed  Google Scholar 

Regulski M, Regulska K, Stanisz BJ, Murias M, Gieremek P, Wzgarda A, et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015;21:1764–75.

Article  CAS  PubMed  Google Scholar 

McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yılmaz İ, Türk M, Baran Ketencioğlu B, Çetinkaya Z, Tutar N, Oymak FS, et al. The presence of underlying asthma should be investigated in patients diagnosed with ACE inhibitor induced cough. Clin Respir J. 2020;14:382–8.

Article  PubMed  Google Scholar 

Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623–35.

Article  CAS  PubMed  Google Scholar 

Xu K, Han H, Luo Y, Ye H, Lin H, Ni L. The angiotensin-converting enzyme inhibitory state promotes the transformation of non-small cell lung cancer blood supply pattern toward vasculogenic mimicry formation. Front Oncol. 2021;11:663671.

Article  PubMed  PubMed Central  Google Scholar 

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc. 2004;292:2217–25.

Article  CAS  Google Scholar 

Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24:3694–701.

Article  CAS  Google Scholar 

Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982–8.

Article  CAS  PubMed  Google Scholar 

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209.

Article  PubMed  PubMed Central  Google Scholar 

Kristensen KB, Hicks B, Azoulay L, Pottegård A. Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study. Circ Cardiovasc Qual Outcomes. 2021;14:e006687.

Article  PubMed  Google Scholar 

Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD, Wang IK, et al. Association between angiotensin-converting enzyme inhibitors and lung cancer—a nationwide, population-based, propensity score-matched cohort study. Cancers. 2020;12:747.

Article  CAS  PubMed Central  Google Scholar 

Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW, Mackiewicz A. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res. 2006;12:4095–102.

Article  CAS  PubMed  Google Scholar 

Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999;81:761–6.

Article  CAS  PubMed  Google Scholar 

Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294–301.

Article  CAS  PubMed  Google Scholar 

Batais M, Almigbal T, Alotaibi K, Alodhayani A, Alkhushail A, Altheaby A, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: a systematic review and meta-analysis. Medicine. 2021;100:e25714.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rachow T, Schiffl H, Lang SM. Risk of lung cancer and renin-angiotensin blockade: a concise review. J Cancer Res Clin Oncol. 2021;147:195–204.

Article  CAS  PubMed  Google Scholar 

Lee SH, Chun KJ, Park J, Kim J, Sung JD, Park RW, et al. Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea. Sci Rep. 2021;11:18576.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, et al. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Netw Open. 2022;5:e2142078.

Article  PubMed  PubMed Central  Google Scholar 

Anderson JL, Knowlton KU, Muhlestein JB, Bair TL, Le VT, Horne BD. Evaluation of treatment with angiotensin converting enzyme inhibitors and the risk of lung cancer: ERACER—an observational cohort study. J Cardiovasc Pharm Ther. 2021;26:321–7.

Article  CAS  Google Scholar 

Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE. 2012;7:e50893.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharm. 2012;74:180–8.

Article  CAS  Google Scholar 

Helgeson SA, Waddle MR, Burnside RC, Debella YT, Lee AS, Burger CD, et al. Association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and lung cancer. South Med J. 2021;114:607–13.

Article  CAS  PubMed  Google Scholar 

Jung MH, Lee JH, Lee CJ, Shin JH, Kang SH, Kwon CH, et al. Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in Korea. J Clin Hypertens. 2021;23:879–87.

Article  CAS  Google Scholar 

Kumar P, Kumar V, Murlidhar F, Fatima A, Jahangir M, Khalid D, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for incidence of lung cancer: a retrospective study. Cureus. 2021;13:e14788.

PubMed  PubMed Central  Google Scholar 

Meng L, Yang B, Qiu F, Jia Y, Sun S, Yang J, et al. Lung cancer adverse events reports for angiotensin-converting enzyme inhibitors: data mining of the FDA adverse event reporting system database. Front Med. 2021;8:594043.

Article  Google Scholar 

Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729–36.

Article  CAS  PubMed  Google Scholar 

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.

Article  CAS  PubMed  Google Scholar 

Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7:1824–32.

Article  PubMed  Google Scholar 

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1–9.

Article  Google Scholar 

Zhang Y, Luo G, Etxeberria J, Hao Y. Global patterns and trends in lung cancer incidence: a population-based study. J Thorac Oncol. 2021;16:933–44.

Article  PubMed  Google Scholar 

Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65–82.

Article  CAS  PubMed  Google Scholar 

Fernandez-Rando M, Herrera MD, Almeida-González CV, Grilo A. Days needed for the disappearance of a cough due to the use of an angiotensin-converting enzyme inhibitor and identification of predisposing factors associated with its appearance in a clinical cohort of hypertensive patients. J Clin Pharm. 2021;61:591–7.

Article  CAS  Google Scholar